BRPI0817535B8 - método in vitro eficiente para obter células apresentadoras de antígenos ativadas (apcs), especialmente células dendríticas (dcs), úteis na preparação de vacinas para o tratamento do câncer - Google Patents
método in vitro eficiente para obter células apresentadoras de antígenos ativadas (apcs), especialmente células dendríticas (dcs), úteis na preparação de vacinas para o tratamento do câncerInfo
- Publication number
- BRPI0817535B8 BRPI0817535B8 BRPI0817535A BRPI0817535A BRPI0817535B8 BR PI0817535 B8 BRPI0817535 B8 BR PI0817535B8 BR PI0817535 A BRPI0817535 A BR PI0817535A BR PI0817535 A BRPI0817535 A BR PI0817535A BR PI0817535 B8 BRPI0817535 B8 BR PI0817535B8
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- useful
- cells
- apcs
- dcs
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 4
- 210000000612 antigen-presenting cell Anatomy 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 101150020229 Apcs gene Proteins 0.000 title abstract 2
- 210000004443 dendritic cell Anatomy 0.000 title abstract 2
- 238000000338 in vitro Methods 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 210000000987 immune system Anatomy 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
- A61K39/464494—Prostate specific antigen [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/07—Heat shock proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Abstract
método in vitro, em duas etapas, para obter células apresentadas de antígenos ativadas (apcs), especialmente as células dendríticas (dcs),úteis na preparação de vacinas para o tratamento do câncer ou outras enfermidades relacionadas ao sistema imunológico. a presente invenção refere-se a um processo ex vivo, rápido eficiente para obter células apresentadoras de antígenos ativadas que são úteis para terapias contra o câncer e doenças relacionadas ao sistema imunológico. ao mesmo tempo, ela se refere a uma composição celular que contribui para estimular as células apresentadoras de antígenos ativadas a induzir uma resposta imune especifica contra os tumores em pacientes com câncer ou outras patologias que envolvam respostas imunes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL200702825A CL2007002825A1 (es) | 2007-09-28 | 2007-09-28 | Metodo para generar vacunas que estimulen el sistema inmune que comprende inducir celulas mononucleares de sangre periferica a que se diferencien a apc, para luego, separar dichas apc y mezclarlas con adyuvantes; extracto de celulas tumorales; y comp |
CL2825/2007 | 2007-09-28 | ||
PCT/EP2008/062909 WO2009040413A2 (en) | 2007-09-28 | 2008-09-26 | An ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0817535A2 BRPI0817535A2 (pt) | 2015-03-31 |
BRPI0817535B1 BRPI0817535B1 (pt) | 2020-10-27 |
BRPI0817535B8 true BRPI0817535B8 (pt) | 2021-05-25 |
Family
ID=40261519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0817535A BRPI0817535B8 (pt) | 2007-09-28 | 2008-09-26 | método in vitro eficiente para obter células apresentadoras de antígenos ativadas (apcs), especialmente células dendríticas (dcs), úteis na preparação de vacinas para o tratamento do câncer |
Country Status (11)
Country | Link |
---|---|
US (2) | US20100303868A1 (pt) |
EP (1) | EP2222331A2 (pt) |
AR (1) | AR068984A1 (pt) |
AU (1) | AU2008303453B2 (pt) |
BR (1) | BRPI0817535B8 (pt) |
CA (1) | CA2700942A1 (pt) |
CL (1) | CL2007002825A1 (pt) |
IL (1) | IL204821A (pt) |
MX (1) | MX2010003415A (pt) |
NZ (1) | NZ584606A (pt) |
WO (1) | WO2009040413A2 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010119307A1 (en) * | 2009-04-14 | 2010-10-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for stimulating antigen-specific t cell responses using accelerated co-cultured dendritic cells |
US20130129713A1 (en) | 2010-08-04 | 2013-05-23 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Method of antigen loading for immunotherapy |
US20160017293A1 (en) * | 2012-08-15 | 2016-01-21 | Neostem Oncology, Llc | Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same |
CN105050617A (zh) * | 2012-12-28 | 2015-11-11 | 阿姆弗拉公司 | 免疫原性裂解物的制备方法、获得的裂解物、负载有该裂解物的树突状细胞以及含有该裂解物或树突状细胞的药物组合物 |
EP3167898A1 (en) | 2015-11-11 | 2017-05-17 | IEO - Istituto Europeo di Oncologia Srl | Method for obtaining tumor peptides and uses thereof |
EP3934686A4 (en) * | 2019-03-06 | 2023-04-26 | Universidad de Chile | IMMUNOGENIC FORMULATIONS FOR THE TREATMENT OF CANCER |
IN201921052318A (pt) * | 2019-12-17 | 2019-12-20 | Senthilkumar NATESAN | |
CN113444687A (zh) * | 2021-05-31 | 2021-09-28 | 浙江圣希澳医学科技有限公司 | 穿膜肽介导肿瘤抗原多肽致敏转染cd40l的dc疫苗及dc-ctl方法 |
CN114288396A (zh) * | 2021-12-21 | 2022-04-08 | 皖南医学院第一附属医院(皖南医学院弋矶山医院) | 一种肿瘤个体化dc疫苗、制备方法及应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6121044A (en) * | 1995-07-12 | 2000-09-19 | Dendreon Corporation | Potent antigen presenting cell composition |
US20020155108A1 (en) * | 1998-05-04 | 2002-10-24 | Biocrystal, Ltd. | Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells |
JP2000143534A (ja) | 1998-11-13 | 2000-05-23 | Asahi Chem Ind Co Ltd | 樹状細胞ワクチン及びその製造方法 |
EP1054351A3 (en) | 1999-05-20 | 2003-06-18 | TeraRecon, Inc., A Delaware Corporation | Method and apparatus for classifying intensity values of volume data using a reconfigurable look-up table |
EP1254953A4 (en) * | 1999-12-28 | 2004-06-02 | Toyoshima Kumao | Maturity-triggering agent for immature dendritic cells |
IL140796A0 (en) | 2001-01-08 | 2002-02-10 | Hadasit Med Res Service | An autologous anti-cancer vaccine |
AU2003260426A1 (en) * | 2002-08-16 | 2004-03-11 | Glycotope Gmbh | Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds |
WO2004050855A2 (en) * | 2002-12-04 | 2004-06-17 | Baylor Research Institute | Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors |
JP5623004B2 (ja) * | 2004-10-25 | 2014-11-12 | ベイラー リサーチ インスティテュートBaylor Research Institute | 熱ショックをかけたメラノーマ細胞体が装填された樹状細胞 |
US20070014795A1 (en) * | 2004-12-30 | 2007-01-18 | Dhodapkar Madhav V | Compositions and methods for enhanced dendritic cell maturation and function |
-
2007
- 2007-09-28 CL CL200702825A patent/CL2007002825A1/es unknown
-
2008
- 2008-09-26 NZ NZ584606A patent/NZ584606A/xx not_active IP Right Cessation
- 2008-09-26 WO PCT/EP2008/062909 patent/WO2009040413A2/en active Application Filing
- 2008-09-26 EP EP08804787A patent/EP2222331A2/en not_active Withdrawn
- 2008-09-26 AU AU2008303453A patent/AU2008303453B2/en not_active Ceased
- 2008-09-26 BR BRPI0817535A patent/BRPI0817535B8/pt active IP Right Grant
- 2008-09-26 US US12/680,709 patent/US20100303868A1/en not_active Abandoned
- 2008-09-26 CA CA2700942A patent/CA2700942A1/en not_active Abandoned
- 2008-09-26 MX MX2010003415A patent/MX2010003415A/es active IP Right Grant
- 2008-09-29 AR ARP080104254A patent/AR068984A1/es unknown
-
2010
- 2010-03-28 IL IL204821A patent/IL204821A/en active IP Right Grant
-
2013
- 2013-05-01 US US13/875,119 patent/US9694059B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2009040413A3 (en) | 2009-11-19 |
EP2222331A2 (en) | 2010-09-01 |
US20140072596A1 (en) | 2014-03-13 |
WO2009040413A2 (en) | 2009-04-02 |
IL204821A0 (en) | 2010-11-30 |
US9694059B2 (en) | 2017-07-04 |
CL2007002825A1 (es) | 2008-05-30 |
CA2700942A1 (en) | 2009-04-02 |
BRPI0817535A2 (pt) | 2015-03-31 |
US20100303868A1 (en) | 2010-12-02 |
NZ584606A (en) | 2012-08-31 |
AU2008303453A1 (en) | 2009-04-02 |
AU2008303453B2 (en) | 2013-06-06 |
IL204821A (en) | 2015-04-30 |
AR068984A1 (es) | 2009-12-23 |
BRPI0817535B1 (pt) | 2020-10-27 |
MX2010003415A (es) | 2010-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0817535B8 (pt) | método in vitro eficiente para obter células apresentadoras de antígenos ativadas (apcs), especialmente células dendríticas (dcs), úteis na preparação de vacinas para o tratamento do câncer | |
CY1121789T1 (el) | Νεες ανοσοενισχυτικες συνθεσεις | |
WO2015149944A3 (en) | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant | |
BR112013002298A2 (pt) | complexação de ácidos nucleicos com componentes catiônicos reticulados com dissulfeto para transfecção e estimulação imunológica. | |
CY1116090T1 (el) | Μεθοδος για σχηματισμο γελης φιμπροϊνης μεταξης χρησιμοποιωντας κατεργασια υπερηχων | |
BR112012031727A2 (pt) | conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença. | |
ATE522600T1 (de) | Anti-tumor impfstoff aus normalen chemisch modifizierten cd4+ zellen | |
BR112013031084A2 (pt) | meios e métodos para imunoterapia celular ativa de câncer usando células tumorais mortas por alta pressão hidrostática e células dendríticas | |
NZ616304A (en) | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses | |
BR112012026953A8 (pt) | Composto, uso de um composto, composição farmacêutica, e processo para preparar uma composição farmacêutica | |
BRPI0607551A2 (pt) | vacinas de combinação de helicobacter e circovìrus porcino e métodos de uso | |
BRPI0314373B8 (pt) | produto imunogênico estável para a indução de anticorpos contra uma ou várias proteínas antigênicas em um indivíduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico | |
BR112014008700A2 (pt) | composições úteis no tratamento de nefropatia e processos para preparação das mesmas | |
UA94036C2 (ru) | Фармацевтическая композиция бендамустина, предназначенная для лиофилизации | |
MX2013012219A (es) | Método de administración de vacunas. | |
ECSP088636A (es) | Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer | |
BR112013029417A2 (pt) | composições de vacina de matriz proteica incluindo policátions | |
BRPI0515428A (pt) | terapia por injeção ao tumor de células dendrìticas (dcti) | |
BR112015000585A2 (pt) | cepas mutantes de mycoplasma hyopneumoniae | |
CL2021001564A1 (es) | Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores (divisional de la solicitud no. 201702407) | |
BR112017022755A2 (pt) | formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual | |
BR112012014624A8 (pt) | suspensão homogênea de compostos de imunopotenciação e usos dos destes | |
BR112012015449A2 (pt) | suspensão de monoidrato de calcipotriol, monoidrato de calcipotriol, processo para preparar nanocristais de monoidrato de calcipotriol, e, composição farmacêutica | |
AR041086A1 (es) | Vacuna | |
BRPI0918226A2 (pt) | composição imunogênica, método para produzir uma composição imunogênica, método para elicitar uma resposta imune contra neisseria, uso da composição imunogênica, e, vacina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: UNIVERSIDAD DE CHILE (CL) |
|
B25A | Requested transfer of rights approved |
Owner name: UNIVERSIDAD DE CHILE (CL) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/09/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |